TY  - GEN
AU  - Lachmann,N
AU  - Czarnecki,K
AU  - Brennig,S
AU  - Phaltane,R
AU  - Heise,M
AU  - Heinz,N
AU  - Kempf,H
AU  - Dilloo,D
AU  - Kaever,V
AU  - Schambach,A
AU  - Heuser,M
AU  - Moritz,T
TI  - Deoxycytidine-kinase knockdown as a novel myeloprotective strategy in the context of fludarabine, cytarabine or cladribine therapy
SN  - 1476-5551
PY  - 2016///0224
KW  - Antineoplastic Agents
KW  - adverse effects
KW  - Bone Marrow
KW  - drug effects
KW  - Cladribine
KW  - Cytarabine
KW  - Cytidine Deaminase
KW  - physiology
KW  - Deoxycytidine Kinase
KW  - genetics
KW  - Drug Resistance, Neoplasm
KW  - Genetic Therapy
KW  - HL-60 Cells
KW  - Hematopoietic Stem Cell Transplantation
KW  - Humans
KW  - Vidarabine
N1  - Publication Type: Letter; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1038/leu.2015.108
ER  -